Around 10 million people worldwide are living with Parkinson's disease (PD) 1 , a progressive neurodegenerative disorder characterized by both motor (e.g. bradykinesia, resting tremor, postural instability, rigidity) and non-motor (e.g. memory loss, hyposmia) disabilities. Current PD treatment is limited to motor symptoms management with dopamine replacement or by enhancing the activity of the remaining dopaminergic neurons. No known therapy is available that can slow down the progress or prevent the onset of the disease. Furthermore, PD cases are growing at a fast ever speed and are projected to increase to over 17.5 million by 2040 due to the fast-growing aging population . While aging remains to be the major risk factor of PD, >20 genes have been identified to be associated with the onset and progress of PD , suggesting the potential of discovering disease-modifying PD treatments.